AI Model Predicts Which Breast Cancer Patients Can Skip Unnecessary Surgery

For thousands of women diagnosed with breast cancer each year, the road through treatment follows a familiar and often exhausting sequence: months of chemotherapy before surgery, followed by an operation whose necessity is rarely questioned. Yet in a substantial fraction of patients, the drugs work so well that no viable tumor remains by the time surgeons operate. A new study from Heidelberg University Hospital, published in BMC Cancer, suggests that a carefully constructed machine learning model can identify many of these patients before the operating room, potentially opening the door to less invasive treatment decisions built on data that clinicians already collect every day.

The research, led by Eva Reisig, Lie Cai, Maria Müller, Benedikt Schäfgen and André Pfob of the Breast Unit at Heidelberg’s Department of Obstetrics and Gynecology, focused on a milestone known as pathological complete response, or pCR. When breast cancer patients receive neoadjuvant treatment — chemotherapy or other systemic therapy given before surgery rather than after — pathologists examine the tissue removed during the operation. If they find no residual invasive cancer in the breast or the sampled lymph nodes, the patient is said to have achieved a complete pathological response. This outcome is more than a reassuring label: it is one of the strongest known predictors of long-term survival and freedom from recurrence, and it has become a key endpoint in breast cancer drug trials.

The clinical logic behind the study is straightforward but ambitious. If a model could reliably predict, before surgery, that a patient’s tumor has been completely eradicated, that information could spare her an operation that would remove nothing but scar tissue. Breast-conserving therapy and even sentinel lymph node procedures carry physical and psychological costs, and for patients whose disease has vanished, those costs may buy little benefit. The obstacle has always been accuracy. Clinical examination, ultrasound, mammography and magnetic resonance imaging each offer imperfect glimpses of the tumor’s status, and no single modality is trustworthy enough on its own to justify withholding surgery. The Heidelberg team’s wager was that combining all of these signals — along with patient and tumor characteristics — in a single algorithmic framework might push predictive performance into clinically useful territory.

To build that framework, the researchers assembled a retrospective, single-center cohort of 388 cases of invasive breast cancer treated with neoadjuvant therapy. For each case, they extracted an unusually rich set of 111 variables spanning three imaging modalities — ultrasound, mammography and magnetic resonance imaging — together with histopathological and clinical information such as receptor status and patient demographics. This breadth matters. Much prior work on predicting pCR has leaned on a single imaging technique or a narrow panel of biomarkers, leaving the algorithm blind to complementary information. By pooling findings from the full diagnostic workup that every breast cancer patient already undergoes, the team aimed to approximate the way an experienced multidisciplinary tumor board weighs evidence, but with mathematical consistency.

Raw data alone, however, do not make a model. With 111 candidate variables and fewer than 400 cases, the researchers faced the classic statistical trap of overfitting — the risk that an algorithm learns quirks of its training data rather than genuine biological relationships. Their first line of defense was a Pearson Product-Moment correlation analysis, which identified variables that were essentially measuring the same underlying quantity. Eight features were removed on these grounds, trimming redundancy before any predictive modeling began. The second filter was LASSO regularization, a technique from statistical learning that shrinks the coefficients of weak predictors toward zero and effectively eliminates them, keeping only the variables that earn their place through genuine association with the outcome. After this two-stage selection, 14 variables survived as the final predictors.

The modeling choice itself was deliberately conservative. Rather than deploying a black-box deep learning architecture, the team used logistic regression with an elastic net penalty, abbreviated GLM in the paper. Elastic net regularization blends the variable-selection behavior of LASSO with the ability to handle correlated predictors, making it well suited to clinical datasets where imaging findings and receptor statuses often travel together. Logistic regression also produces transparent, interpretable coefficients — each variable’s contribution to the prediction can be inspected and questioned, a property that matters enormously when the output will inform decisions about whether a patient undergoes surgery. The authors note that this combination of LASSO-based selection and regularized regression yields interesting insights into the predictive potential of individual variables, all of which are available as part of standard clinical practice, with no experimental tests required.

The results offer cautious encouragement. In the total cohort, pathological complete response was confirmed in 158 of 388 cases, a pCR rate of 40.7 percent — a reminder of how common complete tumor eradication already is under modern neoadjuvant regimens. When the final model was evaluated on a validation set of data it had not learned from, it achieved an area under the receiver operating characteristic curve, or AUROC, of 0.76. In practical terms, an AUROC of 0.5 reflects coin-flip performance while 1.0 represents perfect discrimination; 0.76 indicates the model separates responders from non-responders meaningfully better than chance, though not yet with the near-certainty that would allow surgeons to abandon operative assessment outright.

Two secondary metrics sharpen the clinical picture. The model’s false positive rate — the proportion of patients without pCR who were incorrectly flagged as complete responders — was 8.7 percent, a figure the authors highlight because false positives are the dangerous errors in this setting: a patient wrongly predicted to have no residual tumor might be denied a surgery she actually needed. Meanwhile, the positive predictive value reached 75 percent, meaning that when the model declared a complete response, it was right three times out of four. For context, clinical complete response assessed by conventional means has historically lagged well behind pathological confirmation, which is precisely why surgery has remained non-negotiable. A model that confines its confident predictions to cases where it is right three-quarters of the time, while keeping false alarms below nine percent, represents a measurable step toward closing that gap.

The study’s limitations are the natural constraints of its design. It was retrospective and monocentric, drawing on data from a single German institution, which means the model must be validated externally before any change to surgical practice could be contemplated. The pCR rate in the cohort, while within the range reported for modern neoadjuvant therapy, reflects the specific patient mix and treatment protocols of one center. And even a well-calibrated prediction of complete response would need to be weighed against the possibility of residual disease in areas that imaging cannot fully interrogate. The authors are careful to frame their algorithm as a promising approach to improving prediction, not as a replacement for pathological assessment.

Even so, the significance of the work lies less in its headline numbers than in its method and its message. It demonstrates that a parsimonious, interpretable model built exclusively from routinely available data — three imaging modalities plus standard clinicopathological variables — can approach the problem of treatment response prediction with respectable accuracy, without exotic inputs or opaque architectures. As neoadjuvant therapy becomes more effective and more widely used, the population of patients whose tumors vanish before surgery will only grow, and the question of who truly needs an operation will press harder on the field. Studies like this one sketch the statistical scaffolding for that conversation, and they suggest that the path to personalized, response-adapted breast cancer care may run not through futuristic diagnostics, but through smarter use of the data clinicians already hold in their hands.

Subject of Research: Machine learning prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer

Article Title: Machine learning model for the prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer

Article References: Reisig, E., Cai, L., Müller, M., Schäfgen, B., & Pfob, A. (2026). Machine learning model for the prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17115-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17115-7

Keywords: breast cancer, machine learning, neoadjuvant chemotherapy, pathological complete response, predictive medicine, LASSO regularization, logistic regression, MRI, ultrasound, mammography, AUROC, surgery